214
Participants
Start Date
February 27, 2019
Primary Completion Date
March 31, 2026
Study Completion Date
March 31, 2026
Tisotumab Vedotin
Given into the vein (IV)
Bevacizumab
Given via IV
Pembrolizumab
Given via IV
Carboplatin
Given via IV
Cliniques universitaires Saint-Luc, Brussels
Universitair Ziekenhuis Antwerpen (UZA), Edegem
UZ Leuven, Leuven
Erasmus University Medical Center Rotterdam, Rotterdam
University Medical Center Utrecht (UMC Utrecht), Utrecht
Centre Hospitalier Universitaire (CHU) de Liège, Liège
CHU UCL Namur, Namur
Sainte-Elisabeth, Namur
Rigshospitalet, Copenhagen
Grand Hôpital de Charleroi, Charleroi
Grand Hôpital de Charleroi, Loverval
Centre Hospitalier de l'Ardenne, Libramont
AZ Sint-Jan, Bruges
Hospital Universitari Vall d'Hebron, Barcelona
Universitair Ziekenhuis Gent, Ghent
Memorial Sloan Kettering Cancer Center, New York
SUNY Downstate Medical Center, Brooklyn
Vseobecna fakultni nemocnice v Praze, Prague
Hospital Universitario Reina Sofia, Córdoba
Magee-Womens Hospital of UPMC, Pittsburgh
Nemocnice Na Bulovce, Prague
Fox Chase Cancer Center, Philadelphia
IEO Istituto Europeo di Oncologia, Milan
Carilion Clinic, Roanoke
University of North Carolina Chapel Hill, Chapel Hill
Hospital 12 De Octubre, Madrid
St Francis Hospital Cancer Center, Greenville
Hospital Universitario Virgen de la Arrixaca, El Palmar
Augusta University, Augusta
Baptist MD Anderson Cancer Center, Jacksonville
Ohio State University Wexner Medical Center, Hilliard
Cleveland Clinic, Cleveland
Cleveland Clinic, Cleveland
University of Cincinnati Physicians Group, Cincinnati
Indiana University School of Medicine, Indianapolis
Billings Clinic Cancer Center, Billings
Montana Cancer Consortium, Billings
University of Chicago, Chicago
University of Kansas Medical Center, Westwood
Oschner Clinic, New Orleans
Fakultni nemocnice Ostrava, Ostrava-Poruba
Fakultni nemocnice Olomouc, Olomouc
Istituto Nazionale Tumori Fondazione G. Pascale, Napoli
Huntsman Cancer Center, Salt Lake City
Arizona Oncology Associates, Phoenix
Olive View - UCLA Research and Education Institute, Sylmar
Univ California, Irvine Medical Center, Orange
Azienda Ospedaliera Cannizzaro, Catania
Dana-Farber Cancer Institute, Boston
Brown University - Women's and Infant Hospital, Providence
Universitaire Ziekenhuizen Leuven,, Leuven
Cork University Hospital, Cork
University Hospital Waterford, Waterford
AMC Medical Research, Amsterdam
Fakultni nemocnice Olomouc, Olomouc
Vseobecna fakultni nemocnice v Praze, Prague
Fakultni nemocnice Bulovka, Prague
Mater Misericordiae University Hospital, Dublin
Waterford Regional Hospital, Waterford
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome
Amsterdam UMC, Locatie AMC, Amsterdam
Universitair Medisch Centrum Groningen (UMCG), Groningen
Radboudumc, Nijmegen
Erasmus Medisch Centrum, Rotterdam
UMC Utrecht, Utrecht
Baskent University Adana Application and Research Center, Adana
Baskent University Ankara Hospital, Ankara
Velindre Cancer Centre, Cardiff
Beatson West of Scotland Cancer Centre, Glasgow
Royal Marsden Hospital- Sutton, Sutton
Collaborators (1)
Genmab
INDUSTRY
European Network of Gynaecological Oncological Trial Groups (ENGOT)
OTHER
Belgian Gynaecological Oncology Group
OTHER
GOG Foundation
NETWORK
Merck Sharp & Dohme LLC
INDUSTRY
Seagen, a wholly owned subsidiary of Pfizer
INDUSTRY